ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Targeting JAK-STAT Pathways with Tofacitinib Provides a Novel Approach for Conditioning in Allogeneic BMT Recipients.

H. Xu, A. Merchak, M. Xu, C. Mort, T. Dowling, L. Kahn, M. Binion, A. Chhabra, Y. Wen, Y. Huang, S. Ildstad.

Institute for Cellular Therapeutics, University of Louisville, Louisville, KY

Meeting: 2017 American Transplant Congress

Abstract number: A141

Keywords: Bone marrow transplantation, Mice, Tolerance

Session Information

Date: Saturday, April 29, 2017

Session Name: Poster Session A: Immunosuppression

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall D1

Related Abstracts
  • Tofacitinib-Loaded Solid Lipid Nanoparticles Inhibits Dendritic Cell Antigen Presenting Functions and Achieve Selective In Vivo Targeting.
  • Tolerogenic Interactions Between Host CD8+Myeloid Dendritic Cells and Natural Killer T Cells Are Required for Acceptance of Combined Organ and Bone Marrow Transplants After TLI Conditioning.

Hematopoietic chimerism achieved by bone marrow transplantation (BMT) induces donor-specific tolerance to solid organ grafts. We previously demonstrated that by targeting recipient immune cells (T, NK cells and macrophages) total body irradiation (TBI) can be reduced to safe and clinically acceptable levels in a mouse BMT model. Therefore, we hypothesized that various immune signalling pathways may be novel targets for mixed chimerism as an alternative to immune cell depletion. B6 (H2b) mice were nonmyeloablatively conditioned with 300cGy TBI (day 0) and cyclophosphamide (CyP, day +2) in combination with different pathway inhibitors (day 0 to +9). 15 x 106 bone marrow cells from MHC-disparate BALB/c (H2d) mice were transplanted on day 0. With 300cGy/CyP, 100% engraftment only occurred in recipients treated with JAK3/1/2 inhibitor [tofacitinib (Tofa)], but not with inhibitors of MEK, BTK, PI3K/mTOR, or S1P/S1P1. The JAK/STAT pathway serves a fundamental role in regulation of cell growth and differentiation by transducing signals from extracellular cytokines to their transmembrane receptors, and then to the nucleus. With Tofa, 100% and 58.3% of recipients engrafted with 200 and 100 cGy TBI plus CyP, respectively. Donor chimerism was 57.7 ± 10.8%, 22.7 ± 14.5%, and 3.8 ± 1.2% with 300, 200, 100cGy TBI plus Tofa/CyP at 1 month, respectively. When host T cells were depleted with anti-αβTCR in addition to Tofa/CyP, 100% engraftment regained with 100cGy TBI. The level of donor chimerism with Tofa/anti-αβTCR/100cGy/CyP was significantly higher at 1 month post BMT (8.9 ± 8.7%, P < 0.0001) compared to Tofa/100cGy/CyP conditioning. Engrafted animals exhibited multilineage cell production, including donor T, B, NK cells, macrophages, and granulocytes. Chimerism remained stable up to 6 months. Moreover, specific Vβ5.[frac12] and Vβ11 clonal deletion was detected in host T cells in all chimeric mice, indicating central tolerance to donor alloantigens. Targeting JAK3/1/2 with Tofa can decrease TBI dose to a minimum to achieve mixed chimerism. Tofa and T cell depletion have a synergistic effect to enhance alloengraftment, suggesting that this JAK inhibitor targets cells other than T cells, including innate immune cells. Our study may have a significant impact on the development of immune-based nonmyeloablative conditioning strategies for tolerance induction.

CITATION INFORMATION: Xu H, Merchak A, Xu M, Mort C, Dowling T, Kahn L, Binion M, Chhabra A, Wen Y, Huang Y, Ildstad S. Targeting JAK-STAT Pathways with Tofacitinib Provides a Novel Approach for Conditioning in Allogeneic BMT Recipients. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Xu H, Merchak A, Xu M, Mort C, Dowling T, Kahn L, Binion M, Chhabra A, Wen Y, Huang Y, Ildstad S. Targeting JAK-STAT Pathways with Tofacitinib Provides a Novel Approach for Conditioning in Allogeneic BMT Recipients. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/targeting-jak-stat-pathways-with-tofacitinib-provides-a-novel-approach-for-conditioning-in-allogeneic-bmt-recipients/. Accessed February 27, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.